Avycaz
Active Ingredient(s): Ceftazidime + AvibactamFDA Approved: * February 25, 2015
Pharm Company: * CEREXA
Category: Antibiotics
Avibactam is a non-β-lactam β-lactamase inhibitor[2] developed by Actavis (now Teva) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.